Perspective Therapeutics Inc [CATX] stock is trading at $2.39, up 8.14%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CATX shares have gain 7.17% over the last week, with a monthly amount glided 2.58%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, BTIG Research started tracking the stock with Buy rating on October 10, 2025, and set its price target to $14. On March 13, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $10 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $15 on March 07, 2025. BofA Securities downgraded its rating to a Neutral and reduced its price target to $5 on November 25, 2024. UBS started tracking with a Buy rating for this stock on October 24, 2024, and assigned it a price target of $20. In a note dated October 01, 2024, Wedbush initiated an Outperform rating and provided a target price of $25 on this stock.
Perspective Therapeutics Inc [CATX] stock has fluctuated between $1.60 and $5.39 over the past year. Currently, Wall Street analysts expect the stock to reach $10.5 within the next 12 months. Perspective Therapeutics Inc [AMEX: CATX] shares were valued at $2.39 at the most recent close of the market. An investor can expect a potential return of 339.33% based on the average CATX price forecast.
Analyzing the CATX fundamentals
Perspective Therapeutics Inc [AMEX:CATX] reported sales of 1.07M for the trailing twelve months, which represents a drop of -43.36%. Gross Profit Margin for this corporation currently stands at -1.5% with Operating Profit Margin at -184.63%, Pretax Profit Margin comes in at -204.47%, and Net Profit Margin reading is -197.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.39 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.24 points at the first support level, and at 2.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.48, and for the 2nd resistance point, it is at 2.56.
Ratios To Look Out For
For context, Perspective Therapeutics Inc’s Current Ratio is 8.66. Further, the Quick Ratio stands at 8.66, while the Cash Ratio is 2.22. Considering the valuation of this stock, the price to sales ratio is 166.05, the price to book ratio is 0.73.
Transactions by insiders
Recent insider trading involved Hunt Jonathan Robert, Chief Accounting Officer, that happened on Nov 13 ’25 when 11000.0 shares were purchased. Director, Williamson Robert F III completed a deal on Nov 12 ’25 to buy 9498.0 shares. Meanwhile, Chief Executive Officer Spoor Johan M. bought 22026.0 shares on Mar 28 ’25.
